Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Open in API
Filings indexed 666 across all filing types
Latest filing 2026-05-19 Declaration of Voting R…
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 89% confidence The document is a Form 8-K current report filed under Item 5.07 “Submission of Matters to a Vote of Security Holders,” which provides the detailed voting results for the proposals at the 2026 Annual Meeting of Stockholders. It is clearly an announcement of shareholder voting outcomes, matching the category for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-19 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K
Regulatory Filings Classification · 90% confidence The document is a U.S. SEC Form 8-K “Current Report” by Larimar Therapeutics, Inc. It references the furnishing of a press release for quarterly results (Item 2.02) and an attached investor slide presentation (Item 8.01) via exhibits 99.1 and 99.2. It does not contain the full earnings release text or financial statements itself, but serves as a regulatory filing to report these events. Under the classification rules, such an SEC 8-K with referenced exhibits falls under the general Regulatory Filings category rather than ER (earnings release) or IP (investor presentation) since those materials are merely furnished as exhibits.
2026-05-14 English
S-8 - Larimar Therapeutics, Inc. (0001374690) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans. It includes details about the registration of additional shares under the company's 2020 Equity Incentive Plan. The document references incorporation by reference of other filings such as the Annual Report on Form 10-K and Current Reports on Form 8-K, but this document itself is a registration statement for securities issuance, not a financial report or earnings release. It is not an announcement of a report but a regulatory filing related to securities registration. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (11,477 characters) and content confirm it is a substantive filing, not a brief announcement or certification.
2026-03-19 English
10-K - Larimar Therapeutics, Inc. (0001374690) (Filer)
Annual Report FY 2025
2026-03-19 English
8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that the company announced its financial results and operational highlights for the fourth quarter of 2025 and the year ended December 31, 2025. It also references a press release as Exhibit 99.1. The document itself is short (3756 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis. According to the rules, such a document is classified as an Earnings Release (ER) because it is the initial announcement of quarterly/periodical financial results with key highlights only, not a full interim or annual report. Therefore, the correct classification is ER with high confidence.
2026-03-19 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.